The reports have been updated with the most recent Ukraine-Russia War impact on market growth for all 27+ industries. The reports also provide possible solutions and opportunities for surviving this crisis.

Avail a limited period discount of 33% on our uniquely designed Opportunities and Strategies market research reports. Contact us today and make winning strategies!

The vascular endothelial growth factor inhibitor market is forecasted to achieve significant growth in the coming few years with a forecast CAGR (compound annual growth rate) of more than 8%, as per The Business Research Company’s market report!

Read More On The Vascular Endothelial Growth Factor Inhibitor Market Report 2022 – https://www.thebusinessresearchcompany.com/report/vascular-endothelial-growth-factor-inhibitors-global-market-report-

The Vascular Endothelial Growth Factor Inhibitor Market Size In 2022 And Forecast

The global vascular endothelial growth factor inhibitor market is expected to grow from $7.51 billion in 2021 to $8.27 billion in 2022 at a compound annual growth rate (CAGR) of 10.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, affecting many markets across the globe. The vascular endothelial growth factor (VEGF) inhibitor market is expected to reach $11.30 billion in 2026 at a CAGR of 8.1%.

The vascular endothelial growth factor inhibitor market consists of sales of vascular endothelial growth factor inhibitor biosimilars.

Request for A Sample Of The Global Vascular Endothelial Growth Factor Inhibitor Market Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3437&type=smp

Rise In The Prevalence Of Cancer And Macular Degeneration Disease Is Driving The Growth Of The Vascular Endothelial Growth Factor Inhibitor Market

For instance, according to this systematic review and meta-analysis, age-related macular degeneration affects 8-7% of the global population, with the illness affecting 196 million individuals in 2020 and rising to 288 million by 2040. Furthermore, according to the American Cancer Society, in 2019, around 606,880 deaths were caused in USA due to prevalence of the cancer. The Cancer Research UK predicts that there will be 27.5 million new cases of cancer each year by 2040. Anti-vascular endothelial growth factor (anti-VEGF) agents halt the progression of the disease and improve vision. Vascular endothelial growth factor inhibitor market slows and restricts tumor growth during cancers. Hence, the rising prevalence of cancer along with macular degeneration disease aids in the growth of the vascular endothelial growth factor inhibitor market over the forecast period.

Competitive Landscape And The Regional Analysis Of The Vascular Endothelial Growth Factor Inhibitor Market

Major players in the vascular endothelial growth factor inhibitor market are Pfizer, Amgen, Roche, Xbrane Biopharma AB, Genentech Inc., AstraZeneca plc, Bayer AG, Eli Lilly and Company and Allergan plc.

Additionally, as per TBRC’s research – North America was the largest region in the vascular endothelial growth factor inhibitor market in 2021 holding the largest market share and Middle East is expected to be the fastest-growing region in the forecast period.

The Vascular Endothelial Growth Factor Inhibitor Global Market Report 2022  covers regional data on key drivers, opportunities, and strategies for the seven major regions of the world that are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the vascular endothelial growth factor inhibitor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The report includes market size and forecast market shares for all the regions and countries with respect to the major players of the vascular endothelial growth factor inhibitor market.

Developing New Products – A Key Trend In The Vascular Endothelial Growth Factor Inhibitor Market

Key players operating in the industry are undergoing various collaborations and partnerships to expand their product portfolio by developing new products.

Vascular Endothelial Growth Factor Inhibitor Market Segmentation By The Business Research Company

1) By Drug Type: Avastin, Tecentriq, Cometriq, Eylea, Others

2) By Route of Administration: Oral, Intravenous

3) By Application: Oncology, Ophthalmology, Others

Here Are Some Reports Related To The Vascular Endothelial Growth Factor Inhibitor Market –

Colorectal Cancer Drugs Global Market Report 2022

Biosimilar Growth Hormones Global Market Report 2022

Biosimilars Global Market Report 2022

Get In Touch With Us – Call us at:

Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708

Found this article helpful? Share it on: